

**COMPARISON OF CCKAR EXPRESSION IN NEOPLASTIC AND NON NEOPLASTIC LESIONS OF GALL BLADDER****<sup>1</sup>Dr. Pankhudi Gupta and <sup>2</sup>Dr. Anju Chandra**

Assistant Professor, Department of Pathology Rajkiya Medical College, Jalaun.

**\*Corresponding Author: Dr. Pankhudi Gupta**

Assistant Professor, Department of Pathology Rajkiya Medical College, Jalaun.

Article Received on 01/10/2021

Article Revised on 21/10/2021

Article Accepted on 11/11/2021

**ABSTRACT**

Gall bladder carcinoma is considered as the fifth most common gastro-intestinal neoplasm and most common biliary tract malignancy in world. Spread of gall bladder carcinoma (GBC) to the liver parenchyma and the adjacent internal organs is due to lack of serosa in gall bladder wall and cholecystic veins draining into liver portal vein. Also, Incidence of Gall bladder cancer shows striking geographical predilections, with highest figures found in India and Chile and relatively low level seen in many western countries. Regulatory peptide receptors have now attracted interest of oncologists as a new promising approach for cancer pathology, imaging and therapy. CCKAR encodes a G-protein-coupled receptor that binds cholecystikinin (CCK) family of peptide hormones and also is a major physiological mediator of pancreatic growth and enzyme secretion, smooth muscle contraction of the gallbladder and stomach. Although cholecystikinin (CCK) is a potent modulator of gallbladder contractility and plays a potential role in pancreatic carcinogenesis through CCK type-A receptor (CCKAR), its role in gallbladder cancer (GBC) is still unknown and immunohistochemical detection of CCKAR in the gallbladder has been less evaluated. The aim of study is to compare expression of CCKAR in neoplastic and non neoplastic lesions of gall bladder. This case-control study included 100 samples: 50 from GBC and 50 from Chronic cholecystitis. Expression of CCKAR was analyzed by immunohistochemistry. There was a significant difference in CCKAR expression between chronic cholecystitis and GBC. So, it has future prognostic and therapeutic implications in the management of GBC.

**KEYWORDS:** Cholecystikinin, cholecystikinin type-A receptor, gallbladder cancer, chronic cholecystitis.**INTRODUCTION**

Gall bladder carcinoma is considered as the fifth most common gastro-intestinal neoplasm and the most common biliary tract malignancy in the world.<sup>[1]</sup> As clinical symptoms of carcinoma can be non-specific, the diagnosis is usually late, which results in poor prognosis. Spread of gall bladder carcinoma (GBC) to the liver parenchyma and the adjacent internal organs is due to lack of serosa in gall bladder wall, cholecystic veins draining into liver portal vein, lymphatics from GB draining into the liver.<sup>[2]</sup> Gallbladder carcinoma is highly lethal, as anatomic factors promote early local spread. The tumor spreads easily, invades the liver and surrounding structures including the biliary tree contributing to its high mortality. The median survival is 6 months, indicating that the majority of patients present with advanced disease. Despite the widespread use of modern imaging techniques, early diagnosis is rare because there are no specific signs and symptoms, and many gallbladder carcinomas are not diagnosed preoperatively.

Gall bladder cancer shows a three folds higher incidence in females,<sup>[3]</sup> and also shows striking geographical

predilections in its incidence. Highest figures are found in India and Chile but a relatively low level is seen in many of the western countries.<sup>[4]</sup> There is a high incidence in northern India, along the gangetic belt,<sup>[5]</sup> for this tumor. Also, incidence of carcinoma gallbladder varies in different geographic regions, and racial and ethnic groups. In India, it is the most common form of biliary malignancy and fifth most common gastrointestinal carcinoma in women.<sup>[6-8]</sup> and third most common carcinoma of the digestive tract in Eastern UP and Western Bihar.

Cholelithiasis, especially untreated chronic symptomatic gallstones, with inflammation is considered as one of the main risk factors of gallbladder cancer. Most of the gallbladder carcinomas have regional disease or distant metastases at presentation with poor prognosis.

Cholecystikinin (CCK) and gastrin families of peptides act as hormones and neuropeptides on central and peripheral CCK receptors to mediate secretion and motility in GIT in physiological response to a normal meal. CCK-A receptor, found predominantly in the GI system and selective areas of the CNS, have high affinity

for CCK and the non peptide antagonist L-364,718. The physiological functions of gall bladder are done through different receptors. The main neurohormonal mechanisms regulating the motility of the gallbladder are the vagus and splanchnic nerves and the hormone CCK. The subtypes of receptors for CCK in the human pancreas and gallbladder are different. The human pancreas predominantly expresses CCK-B receptor, whereas CCK-A receptor are localized in the human gallbladder muscle.<sup>[9]</sup> It is now a known fact that gallbladder has high concentration of CCK-A receptor.<sup>[10]</sup> Although, CCK-A receptor does not modulate the susceptibility of cancer gallbladder.<sup>[11]</sup> But their role in gallbladder malignancy and other gall bladder lesions still remains undecided. Molecular studies in high incidence areas, and in subsets of high risk gallbladder disease patients, may help us to predict the possibility of gall stone disease developing into severity and increasing ailments of patients through social, economical, financial and emotional stigma. This may show for measures to be taken in developing new therapeutic strategies or screening for developing gall bladder pathologies at the earliest.

The aim of study was to evaluate and compare the expression of CCK-A receptor in non-neoplastic and neoplastic lesions of gall bladder.

## MATERIALS AND METHODOLOGY

### Patients

This case-control study included patients undergoing surgery for gall bladder carcinoma and gall stone disease from November 2018 to December 2019 in the Department of Pathology in Rajkiya (Government) Medical College, Jalaun. The sample size was calculated as 50 for each group. The study population comprised of patients undergoing surgical procedure for gall bladder diseases either through open or laparoscopic procedures. Specimen were subjected to routine histopathological processing, diagnosed cases of adenocarcinoma of gall bladder were taken. Non-neoplastic cases which included chronic cholecystitis with or without cholelithiasis were taken as control. Patients with double malignancy, immunodeficiency diseases or any other associated chronic debilitating disorder which is likely to interfere with detection of marker were excluded.

### Immunohistochemistry

3-4  $\mu$ m sections from paraffin embedded blocks were cut and placed on polylysine-coated slides and used for immunohistochemical staining. Primary antibody and a secondary kit used for detection of CCK-A receptor (CCK-A receptor (H-60) antibody; sc- 33220) were from Santa Cruz, and the Super Sensitive Link-Lable IHC Detection System (QD000-5L) was from Biogenex, San Ramon, CA, USA.

Briefly, all sections were dewaxed and rehydrated in xylene and graded alcohol, and placed under slow running tap water for 15 minutes followed by citrate

buffer (pH 6.0) retrieval by the microwave method. The sections were allowed to cool at room temperature and washed 3 times with Tris buffer (TBS, pH 7.6). Then they were incubated with peroxidase block for 20 minutes to check internal peroxidase activity. After washing with TBS, these sections were incubated with power block for 15 minutes to block nonspecific staining. Excess power block was removed and then the sections were immediately incubated with primary antibody at 1:200 dilution in TBS overnight at 4°C. After washing with TBS, the sections were incubated with multilink for 30 minutes and washed with TBS followed by secondary antibody incubation again for 30 minutes. After washing, color was developed using diaminobenzidine (DAB) as the chromogen. Finally, slides were washed and counterstained with Harris hematoxylin. For positive control, a section known to stain positively on the gallbladder muscle layer component was included in each batch of staining, and for negative control primary antibody was replaced with TBS. Evaluation of IHC staining pattern. The results were evaluated qualitatively, with staining pattern as positive or negative.

## RESULTS

Out of 100 subjects enrolled in the study, a total of 50 neoplastic were taken as cases and whereas remaining 50 non-neoplastic controls. Among neoplastic cases, all adenocarcinomas were taken and among non neoplastic chronic cholecystitis were taken. Age of patients ranged from 30 to 70 years. CCKAR expression, in neoplastic cases, by immunostaining showed 76% positive cases while in non-neoplastic only 42% cases showed positivity. On statistical analysis, there was a significant difference in CCKAR expression between both the groups. *p* value came out to be significant on comparison between neoplastic and non neoplastic groups.

**Table 2: CCKAR expression in neoplastic and non neoplastic group.**

Group	N	Mean	Standard Deviation
Neoplastic	50	4.42	2.408
Non neoplastic	50	1.78	1.250

*p* value= <0.001(S)

## DISCUSSION

Gallbladder carcinoma is considered fifth most common neoplasm of the digestive tract and it has an overall incidence of 3 per 100000 people. Also it is suspected preoperatively in only 30% of all patients.<sup>[11]</sup> It is the most common cancer of the biliary tract.<sup>[11]</sup> Gall bladder Carcinoma is found in 0.2%-3% of all cholecystectomies and 0.09%-2% of all laparoscopic cholecystectomies.<sup>[12,13]</sup>

Nearly 70% of cases are diagnosed using postoperative incidental findings by a pathologist and are termed as incidental or occult gallbladder carcinomas. It is observed that only 15%-47% of the preoperatively

known gallbladder carcinomas are suitable for resection.<sup>[14]</sup> Majority of symptomatic patients with malignant gallbladder disease have an incurable tumor. So, the outcome of gallbladder carcinoma is poor, and overall 5-year survival rate is less than 5%.<sup>[15]</sup>

Gallbladder carcinoma is described in up to 3.4% of autopsies conducted on cholelithiasis patients over 60 years of age.<sup>[16]</sup> 2 peaks are usually observed in gallbladder tumor incidence. The first peak occurs at 50-60 years of age and second at 70-80 years of age, with a higher prevalence among women.<sup>[17-19]</sup> The incidence rates are extraordinarily high in Mapuche Indians in Chile, South America. This population exhibits the highest rate of gallbladder cancer which is 12.3/100000 for males and 27.3/100000 for females.<sup>[20]</sup> So, it is observed that countries with a higher rate of cholecystectomy have a lower rate of gallbladder carcinomas.

Different modes of lymphatic spread were described by Fahim *et al.*<sup>[21]</sup> based on the anatomical work in fetuses of Clermont in 1909 and the 3 pathways described by Ito *et al.*<sup>[22]</sup> in adult cadavers.

Shirai *et al.*,<sup>[23]</sup> identified the regional lymphatic system of the gallbladder by intraoperative vital staining.

Also, a series of studies by Kano M *et al.*,<sup>[24]</sup> in 2002 had shown that formation of cholesterol supersaturated bile in subjects with cholesterol gallstone disease is causatively related to decreased gallbladder contractility and mucin hypersecretion by the gallbladder. Supersaturated bile may modify the Composition of gallbladder membranes so that the transduction of smooth muscle regulatory signals is impaired, and also may enhance the inflammation-induced mucin secretion by gallbladder. This showed that CCKAR has strong association with gall stone formation which may indirectly lead to carcinogenesis.

Also, a study conducted by Schulz S *et al.*,<sup>[25]</sup> in 2005 showed that the presence of CCK1 receptors was rarely detected in human tumors except for carcinoids, insulinomas, pituitary adenomas, and meningiomas. So, it was observed that overexpression of CCK receptor is definitely having association with some form of carcinogenesis.

The findings of this study, has thus concluded that positivity of CCKAR expression have a significant role in differentiating neoplastic and non neoplastic lesions of gall bladder. Detection of CCKAR in normal gall bladder and in epithelial dysplasia should also be done to determine whether CCKAR expression progressively increases with the onset of changes in the gallbladder epithelium. So, we found that coexpression of CCK, *in situ* detection of CCKAR, secondary signalling pathways linked to it and the mechanism of its up-regulation, should also be examined to explore the involvement of

this receptor in the development and progression of GBC.

## CONCLUSION

The incidence of gall bladder carcinoma remains much higher in Indian than in the western world. Also a more delayed presentation thus carrying worse prognosis is observed. So, It is essential that it is recognized early and differentiated from other benign pathologies. Out of all available modalities, image-guided biopsies play the most important role in diagnosis and follow-up.

CCK is admittedly one of many regulatory peptides or hormones involved in GBC. Present study thus showed that positivity of CCKAR expression have a significant role in differentiating non-neoplastic from neoplastic lesions of gallbladder. CCKAR is significantly overexpressed in GBC and encourages the inclusion of more peptides and hormones in future studies. In addition, the over-expression of CCKARs in most cases of GBC may suggest the use of receptor antagonists for tumor localization, clinical assessment, and receptor-based delivery of therapeutic agents to treat GBC.

## REFERENCES

1. Furlan A, Ferris JV, Hosseinzadeh K, Borhani AA Gall bladder carcinoma update: multimodality imaging evaluation, staging, and treatment options. *Am J Roentgenol*, 2008; 191(5): 1440-1447.
2. Dwivedi AN, Jain S, Dixit R Gall bladder carcinoma: aggressive malignancy with protean loco-regional and distant spread. *World J Clin Cases*, 2015; 3(3): 231.
3. Pesic M, Karanikolic A, Djordjevic N, Gmijović D, Bašić H. Clinical characteristics of primary carcinoma of thegallbladder. *FactaUniversitatis. Series: Medicine and Biology*, 2002; 9: 227-230.
4. Goldin RD, Roa JC. Gallbladder cancer: a morphological and molecular update. *Histopathology*, 2009; 55: 218-229.
5. Dhir V, Mohandas KM.: Epidemiology of digestive tract cancers in India IV, gallbladder and pancreas. *Indian J Gastroenterol*, 1999; 18: 24-28.
6. Shukla VK, Khandelwal C, Roy SK. Primary CA of the gallbladder: A review of a 16-year period at the university hospital. *Jour SurgOncol*, 1985; 28: 32-5.
7. Kapoor VK, McMichael AJ. Gallbladder cancer: an India disease. *Natl Med J India*, 2003; 16(4): 209-13.
8. Mishra S, Chaturvedi A, Misra NC. CA of the gallbladder. *Lancet Oncol*, 2003; 4: 167-76.
9. Pandey SN, Jain M, Nigam P. Genetic polymorphisms in GSTM1, GSTT1, GSTP1, GSTM3 and the susceptibility to gallbladder cancer in North India. *Biomarkers*, 2006; 11: 250-61.
10. Tang C, Biemond I, Lamers C. Cholecystokinin receptors in human pancreas and gallbladder muscle: A comparative study. *Gastroenterology*, 1996; 111(6): 1621-1626.

11. Srivastava A, Pandey SN, Dixit M, Choudhuri G, Mittal B. Cholecystokinin receptor A gene polymorphism in gallstone disease and gallbladder cancer. *Journal of Gastroenterology and Hepatology*, 2008; 23: 970–75.
12. Steigerwalt RW, Goldfine ID, Williams JA. Characterization of Cholecystokinin receptors on bovine gallbladder membranes. *Am J PhysiolGastrointest Liver Physiol*, 1984; 247: G709–14.
13. Varshney S, Butturini G, Gupta R. Incidental carcinoma of the gallbladder. *Eur J Surg Oncol*, 2002; 28: 4-10. [PMID: 11869005 DOI: 10.1053/ejso.2001.1175]
14. Romano F, Franciosi C, Caprotti R, De Fina S, Porta G, Visintini G, Uggeri F. Laparoscopic cholecystectomy and unsuspected gallbladder cancer. *Eur J Surg Oncol*, 2001; 27: 225-228. [PMID: 11373097]
15. Toyonaga T, Chijiwa K, Nakano K, Noshiro H, Yamaguchi K, Sada M, Terasaka R, Konomi K, Nishikata F, Tanaka M. Completion radical surgery after cholecystectomy for accidentally undiagnosed gallbladder carcinoma. *World J Surg*, 2003; 27: 266-271. [PMID: 12607049]
16. Mekeel KL, Hemming AW. Surgical management of gallbladder carcinoma: a review. *J Gastrointest Surg*, 2007; 11: 1188-1193. [PMID: 17712596 DOI: 10.1007/s11605-007-0115-1]
17. Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. *Ann Surg*, 2000; 232: 557-569 [PMID: 10998654]
18. Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, Saka B, Losada H, Bagci P, Adsay NV. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. *Mod Pathol*, 2011; 24: 1069-1078. [PMID: 21532545 DOI: 10.1038/modpathol.2011.68]
19. Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Arista Urista G, Nervi F. Epidemiology and molecular pathology of gallbladder cancer. *CA Cancer J Clin*, 2001; 51: 349-364. [PMID: 11760569]
20. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. *Clin Epidemiol*, 2014; 6: 99-109. [PMID: 24634588 DOI:10.2147/CLEP.S37357]
21. Fahim RB, McDonald JR, Richards JC, Ferris DO. Carcinoma of the gallbladder: a study of its modes of spread. *Ann Surg*, 1962; 156: 114-124. [PMID: 13891308]
22. Ito M, Mishima Y, Sato T. An anatomical study of the lymphatic drainage of the gallbladder. *Surg Radiol Anat*, 1991; 13: 89-104. [PMID: 1925922]
23. Shirai Y, Yoshida K, Tsukada K, Ohtani T, Muto T. Identification of the regional lymphatic system of the gallbladder by vital staining. *Br J Surg*, 1992; 79: 659-662. [PMID: 1643479]
24. Kano M, Shoda J, Satoh S, Kobayashi M, Matsuzaki Y, Abei M. Increased expression of gallbladder cholecystokinin: a receptor in prairie dogs fed a high-cholesterol diet and its dissociation with decreased contractility in response to cholecystokinin. *J Lab Clin Med*, 2002; 139: 285- 294.
25. Schulz S, Rocken C, Mawrin C, Schulz S. Immunohistochemical localization of CCK1 cholecystokinin receptors in normal and neoplastic human tissues. *J ClinEndocrinol Metab*, 2005; 90: 6149-6155.